Logo image
Back
Impact of reduced restrictions on buprenorphine prescribing during COVID-19 among patients in a community-based treatment program
Journal article   Open access   Peer reviewed

Impact of reduced restrictions on buprenorphine prescribing during COVID-19 among patients in a community-based treatment program

Kathleen M. Ward, Ayden Scheim, Jonathan Wang, Benjamin Cocchiaro, Katie Singley and Alexis M. Roth
Drug and Alcohol Dependence Reports, v 3, 100055
Jun 2022
DOI: https://doi.org/10.1016/j.dadr.2022.100055
PMID: 35497489
Featured in Collection :   UN Sustainable Development Goals @ Drexel
url
https://doi.org/10.1016/j.dadr.2022.100055View
Published, Version of Record (VoR)CC BY-NC-ND V4.0,  Open

Abstract

Adherence Buprenorphine COVID-19 Opioid use disorder People who use drugs Retention Telemedicine
• Buprenorphine retention improved with less restrictive policies during COVID-19. • Risk of discontinuing buprenorphine was lowest among patients using telemedicine. • Low-threshold access to buprenorphine should continue to be expanded. Medications such as buprenorphine are considered the gold standard for the treatment of opioid use disorders. This study aimed to determine whether less restrictive buprenorphine prescribing practices during the COVID-19 pandemic impacted retention in and adherence to buprenorphine among patients accessing treatment from 2018-2020 at a community-based syringe services program. In this retrospective cohort study, we compared retention in treatment before and during the COVID-19 pandemic. Then, with relaxed restrictions acting as the intervention in a natural experiment, we conducted a sub-analysis of “continuity participants” who accessed treatment services both before and during the COVID-19 period. Records of 418 historical control patients treated with buprenorphine before COVID-19 were compared to 88 patients enrolled during COVID-19 (n=43 remote telemedicine and n=45 remote provider with patient on-site). Cox proportional hazards regressions were used to assess risk factors for treatment discontinuation. The sub-analysis used proportion of days covered (PDC) differences before and during COVID-19 (n=164) for a paired analysis in a nonparametric bootstrap test. The risk of discontinuation was 71% lower in those accessing remote telemedicine during COVID-19 (HR=0.29; CI: 0.18, 0.47) and 51% lower in those accessing their remote provider onsite during COVID-19 (HR=0.49; CI:0.31, 0.77), compared to the historical control group. The average PDC did not significantly differ before and during COVID-19 (difference=2.4%; CI:-0.6%, 5.3%). The risk of discontinuing treatment was lower in both COVID-19 treatment groups compared to historical controls. Less restrictive buprenorphine prescribing guidelines during COVID-19 led to improved retention in care over 6-months.

Metrics

13 Record Views
24 citations in Web of Science
19 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
Web of Science research areas
Psychiatry
Substance Abuse
Logo image